الفهرس 
ARDSOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
Acute respiratory distress syndrome (ARDS) is caused by an inflammatory injury to the lung that causes exudative neutrophilic inflammatory edema, resulting in severe gas exchange impairment and lung compliance abnormalities. The clinical evidence had demonstrated a strong relationship between failure to down-regulate persistent systemic inflammation and worse outcome for patients with ARDS. Non survivors of ARDS have significantly higher levels of broncho-alveolar lavage (BAL) and blood levels of inflammatory cytokines, chemokines and markers of fibrogenesis at ARDS onset that persist for at least 7 days. Considering the fact that inflammation is the main pathogenesis of ARDS, corticosteroids would be a logical choice for the management of ARDS. So, the present study aimed to evaluating the effect of using low dose of methylprednisolone infusion in early ARDS on inflammatory biomarkers including interleukin-6 and high sensitive C-reactive protein over the 7 days and on patients’ outcomes. The present study was carried out as a prospective observational study during the period from January 2015 to April 2016. Forty adult critically ill patients were enrolled in this study after ICU admission at Menoufia university hospital. The study protocol was approved the Ethical Committee of the Department of Anesthesiology, Intensive Care, and Pain Management, Faculty of Medicine, Menoufia University. The patients fulfilled the criteria of ARDS (PaO2/FIO2 less than 200, bilateral pulmonary infiltrates and a normal left ventricular systolic function).